Cargando…

Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel

Untargeted metabolomics is used to refine the development of biomarkers for the diagnosis of cardiovascular disease. Myocardial infarction (MI) has major individual and societal consequences for patients, who remain at high risk of secondary events, despite advances in pharmacological therapy. To mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Samman, Karla N., Mehanna, Pamela, Takla, Emad, Grenier, Jean-Christophe, Chan, Mark Y., Lopes, Renato D., Neely, Megan Lee, Wang, Tracy Y., Newby, L. Kristin, Becker, Richard C., Lordkipanidzé, Marie, Ruiz, Matthieu, Hussin, Julie G., Jolicœur, E. Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233657/
https://www.ncbi.nlm.nih.gov/pubmed/34195679
http://dx.doi.org/10.1016/j.xcrm.2021.100299
_version_ 1783713901469237248
author Samman, Karla N.
Mehanna, Pamela
Takla, Emad
Grenier, Jean-Christophe
Chan, Mark Y.
Lopes, Renato D.
Neely, Megan Lee
Wang, Tracy Y.
Newby, L. Kristin
Becker, Richard C.
Lordkipanidzé, Marie
Ruiz, Matthieu
Hussin, Julie G.
Jolicœur, E. Marc
author_facet Samman, Karla N.
Mehanna, Pamela
Takla, Emad
Grenier, Jean-Christophe
Chan, Mark Y.
Lopes, Renato D.
Neely, Megan Lee
Wang, Tracy Y.
Newby, L. Kristin
Becker, Richard C.
Lordkipanidzé, Marie
Ruiz, Matthieu
Hussin, Julie G.
Jolicœur, E. Marc
author_sort Samman, Karla N.
collection PubMed
description Untargeted metabolomics is used to refine the development of biomarkers for the diagnosis of cardiovascular disease. Myocardial infarction (MI) has major individual and societal consequences for patients, who remain at high risk of secondary events, despite advances in pharmacological therapy. To monitor their differential response to treatment, we performed untargeted plasma metabolomics on 175 patients from the platelet inhibition and patient outcomes (PLATO) trial treated with ticagrelor and clopidogrel, two common P(2)Y(12) inhibitors. We identified a signature that discriminates patients, which involves polyunsaturated fatty acids (PUFAs) and particularly the omega-3 fatty acids docosahexaenoate and eicosapentaenoate. The known cardiovascular benefits of PUFAs could contribute to the efficacy of ticagrelor. Our work, beyond pointing out the high relevance of untargeted metabolomics in evaluating response to treatment, establishes PUFA metabolism as a pathway of clinical interest in the recovery path from MI.
format Online
Article
Text
id pubmed-8233657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82336572021-06-29 Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel Samman, Karla N. Mehanna, Pamela Takla, Emad Grenier, Jean-Christophe Chan, Mark Y. Lopes, Renato D. Neely, Megan Lee Wang, Tracy Y. Newby, L. Kristin Becker, Richard C. Lordkipanidzé, Marie Ruiz, Matthieu Hussin, Julie G. Jolicœur, E. Marc Cell Rep Med Article Untargeted metabolomics is used to refine the development of biomarkers for the diagnosis of cardiovascular disease. Myocardial infarction (MI) has major individual and societal consequences for patients, who remain at high risk of secondary events, despite advances in pharmacological therapy. To monitor their differential response to treatment, we performed untargeted plasma metabolomics on 175 patients from the platelet inhibition and patient outcomes (PLATO) trial treated with ticagrelor and clopidogrel, two common P(2)Y(12) inhibitors. We identified a signature that discriminates patients, which involves polyunsaturated fatty acids (PUFAs) and particularly the omega-3 fatty acids docosahexaenoate and eicosapentaenoate. The known cardiovascular benefits of PUFAs could contribute to the efficacy of ticagrelor. Our work, beyond pointing out the high relevance of untargeted metabolomics in evaluating response to treatment, establishes PUFA metabolism as a pathway of clinical interest in the recovery path from MI. Elsevier 2021-06-04 /pmc/articles/PMC8233657/ /pubmed/34195679 http://dx.doi.org/10.1016/j.xcrm.2021.100299 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Samman, Karla N.
Mehanna, Pamela
Takla, Emad
Grenier, Jean-Christophe
Chan, Mark Y.
Lopes, Renato D.
Neely, Megan Lee
Wang, Tracy Y.
Newby, L. Kristin
Becker, Richard C.
Lordkipanidzé, Marie
Ruiz, Matthieu
Hussin, Julie G.
Jolicœur, E. Marc
Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
title Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
title_full Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
title_fullStr Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
title_full_unstemmed Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
title_short Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
title_sort differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233657/
https://www.ncbi.nlm.nih.gov/pubmed/34195679
http://dx.doi.org/10.1016/j.xcrm.2021.100299
work_keys_str_mv AT sammankarlan differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT mehannapamela differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT taklaemad differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT grenierjeanchristophe differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT chanmarky differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT lopesrenatod differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT neelymeganlee differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT wangtracyy differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT newbylkristin differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT beckerrichardc differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT lordkipanidzemarie differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT ruizmatthieu differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT hussinjulieg differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel
AT jolicœuremarc differentialmodulationofpolyunsaturatedfattyacidsinpatientswithmyocardialinfarctiontreatedwithticagrelororclopidogrel